Completed PHASE2 INTERVENTIONAL 4-arm NCT00612664

Phase II, 2nd Line Melanoma - RAND Monotherapy

A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma

Sponsor: Bristol-Myers Squibb

Conditions Melanoma

Interventions Anti-CD137 (4-1BB) (BMS-663513)

Updated 9 times since 2017 Last updated: Sep 23, 2015 Started: Mar 31, 2008 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Melanoma, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 9 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus C, Denmark , Baltimore, United States , Boston, United States , Calgary, Canada , Charlotte, United States , Edmonton, Canada , Genove, Italy , Homburg / Saar, Germany , Houston, United States , Indianapolis, United States and 21 more locations